Physician profile
Christopher S King
NPI 1700874948
$130,518.75
in general payments reported to CMS, 2019-2025
23 companies · $9,912 in 2025
The $9,912 reported for 2025 was more than what 95% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $25K · 2021: $17K · 2022: $11K · 2023: $27K · 2024: $17K · 2025: $9,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $38K · Consulting Fee: $9,810 · Travel and Lodging: $3,926 · Food and Beverage: $2,554 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,785.00 |
| Consulting Fee | $9,810.00 |
| Travel and Lodging | $3,925.96 |
| Food and Beverage | $2,554.38 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $69,202.54 | 2019-2025 | Tyvaso, Tyvaso, Remodulin |
| Actelion Pharmaceuticals US, INC. | $28,472.69 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,219.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $9,580.49 | 2022-2025 | Winrevair |
| Genentech USA, INC. | $7,626.87 | 2019 | |
| Genentech, INC. | $1,000.00 | 2020 | |
| Eagle Pharmaceuticals, INC. | $337.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.97 | 2019-2024 | |
| Insmed, INC. | $306.83 | 2019-2025 | Arikayce |
| Gilead Sciences, INC. | $185.91 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $60.13 | 2021-2022 | |
| Astellas Pharma US INC | $47.24 | 2020-2025 | Cresemba |
| Abbvie INC. | $25.57 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.47 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $20.93 | 2025 | Uptravi, Opsumit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.73 | 2021 | |
| Advanced Respiratory, INC | $18.34 | 2021 | |
| Shionogi INC | $16.48 | 2021 | |
| Invivyd INC | $14.69 | 2025 | Pemgarda |
| Sandoz INC. | $11.95 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.